Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating safety and efficacy of adalimumab in Chinese patients with moderate to severe Crohn's disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: AbbVie | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED | Results posted: 2019-01-04